NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080224550

Registered date:06/02/2019

Basic Information

Recruitment status completed
Health condition(s) or Problem(s) studied
Date of first enrollment30/01/2019
Target sample size1086
Countries of recruitmentJapan,Asia except Japan,Europe
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Carboplatin, Paclitaxel, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcomeefficacy
Secondary Outcomesafety efficacy

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderFemale
Include criteria
Exclude criteria

Related Information

Contact

Public contact
Name
Address
Telephone
E-mail JPCT@merck.com
Affiliation
Scientific contact
Name
Address
Telephone
E-mail JPCT@merck.com
Affiliation